期刊
TRANSLATIONAL ONCOLOGY
卷 8, 期 3, 页码 196-203出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2015.03.011
关键词
-
类别
资金
- New Drug State Key Project [009ZX09102-205]
- University of Cincinnati
- UCCOM Fund
- [R01CA158372]
Pancreatic cancer remains one of the most intractable cancers, with a dismal prognosis reflected by a 5-year survival of similar to 6%. Since early disease symptoms are undefined and specific biomarkers are lacking, about 80% of patients present with advanced, inoperable tumors that represent a daunting challenge. Despite many clinical trials, no single chemotherapy agent has been reliably associated with objective response rates above 10% or median survival longer than 5 to 7 months. Although combination chemotherapy regimens have in recent years provided some improvement, overall survival (8-11 months) remains very poor. There is therefore a critical need for novel therapies that can improve outcomes for pancreatic cancer patients. Here, we present a summary of the current therapies used in the management of advanced pancreatic cancer and review novel therapeutic strategies that target tumor biomarkers. We also describe our recent research using phosphatidylserine-targeted saposin C-coupled dioleoylphosphatidylserine nanovesicles for imaging and therapy of pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据